Continuous hydromorphone for pain and sedation in mechanically ventilated infants and children

Area of Science:

• Pediatric Critical Care Medicine
• Pharmacology
• Pain Management

Background:

• Continuous infusion hydromorphone is utilized for analgesia in critically ill patients.
• Limited data exists on its specific dosing and efficacy in pediatric populations requiring mechanical ventilation.

Purpose of the Study:

• To delineate the dosing regimens for continuous infusion hydromorphone in mechanically ventilated children.
• To evaluate the efficacy of this analgesic approach using pain scores and assess associated adverse events.

Main Methods:

• A retrospective review was conducted at a tertiary care pediatric hospital.
• Data from 92 critically ill children (<18 years) receiving continuous hydromorphone infusion were analyzed.
• Key outcome measures included hydromorphone dosage, concurrent pain/sedation therapies, Face Legs Activity Cry Consolability (FLACC) pain scores, and adverse drug events.

Main Results:

• The average starting dose was 0.024 mg/kg/h, with a maximum average dose of 0.05 mg/kg/h over a median of 182 hours.
• The majority of patients (66%) had mean daily FLACC scores below 1, indicating effective pain control.
• Patients on extracorporeal membrane oxygenation (ECMO) required significantly higher initial and maximum hydromorphone doses (p=0.001).

Conclusions:

• Continuous infusion hydromorphone serves as an effective adjunctive analgesic in pediatric patients requiring mechanical ventilation.
• The study provides valuable insights into dosing strategies and confirms its utility in managing pain in this vulnerable patient group.